Introduction
Intense Pulsed Light (IPL) and laser devices are widely used in aesthetic clinics, dermatology practices and professional beauty centres. Common applications include hair removal, skin rejuvenation, tattoo removal and skin resurfacing. As these technologies continue to develop, manufacturers must ensure that their products meet applicable European safety, performance and regulatory requirements before being placed on the market.
The European Union Medical Device Regulation (EU) 2017/745, commonly known as the EU MDR, establishes the regulatory framework for medical devices. It also covers certain products without an intended medical purpose through Annex XVI. This is particularly important for IPL and laser manufacturers because some aesthetic equipment is regulated even when it is marketed exclusively for cosmetic applications.
Understanding the EU MDR Framework
The EU MDR introduced more detailed requirements for device safety, clinical evaluation, technical documentation, traceability and post-market surveillance. Manufacturers must demonstrate that their products meet applicable General Safety and Performance Requirements and maintain compliance throughout the product lifecycle.
The regulatory status of an IPL or laser system depends significantly on its intended purpose. Equipment intended for a medical purpose may qualify as a medical device under Article 2 of the MDR. Certain aesthetic products without an intended medical purpose may also fall within the regulation through Annex XVI.
Annex XVI and Aesthetic Equipment
Annex XVI identifies groups of products that do not have an intended medical purpose but are regulated because of their characteristics and associated risks. Group 5 covers specified equipment emitting high-intensity electromagnetic radiation, including infrared, visible light and ultraviolet radiation, intended for use on the human body.
Depending on their intended purpose and technical characteristics, products within this group can include certain equipment used for hair removal, tattoo removal, skin resurfacing and other skin treatments. Manufacturers should assess the exact scope of the applicable provisions rather than assuming that every cosmetic light-based device follows the same regulatory route.
Regulation (EU) 2022/2346 establishes Common Specifications for Annex XVI product groups within its scope. These specifications address risk management, information supplied by manufacturers and product-specific safety requirements. For Group 5 equipment, manufacturers should pay particular attention to the relevant provisions in Annex VI.
Determining the Correct Classification
Classification determines the conformity assessment route and the level of regulatory scrutiny. Medical devices are classified under Annex VIII of the MDR. Active therapeutic equipment may be assessed under Rule 9, depending on the energy it administers or exchanges with the human body and the potential hazards involved.
For applicable Annex XVI Group 5 products, Implementing Regulation (EU) 2022/2347 provides specific classification provisions. Equipment intended exclusively for hair removal is generally classified as Class IIa, while equipment intended for other skin treatments, including tattoo removal and skin resurfacing, is generally classified as Class IIb.
Multifunctional platforms require careful consideration. If a system is intended for hair removal as well as other skin treatments, the manufacturer must evaluate all intended purposes. The complete system should not automatically be classified according to its lowest-risk function.
Preparing Technical Documentation
Technical documentation provides evidence that the manufacturer has addressed the applicable regulatory requirements. Annex II and Annex III of the MDR describe important documentation obligations. The technical file should explain the product's design, intended purpose, manufacturing process, safety characteristics, performance and post-market arrangements.
For IPL and laser equipment, technical documentation may include:
- Device description, model variations and accessories.
- Intended purpose and operating principles.
- Technical specifications and optical output characteristics.
- Design drawings and manufacturing information.
- Risk management documentation.
- Electrical safety and electromagnetic compatibility reports, where applicable.
- Software verification and validation records, where applicable.
- Clinical evaluation or performance evaluation documentation.
- Labelling, warnings and instructions for use.
- Post-market surveillance and vigilance procedures.
All documents should be consistent with the intended purpose and product claims. Marketing materials should not describe treatment applications that are unsupported by the technical documentation and relevant evidence.
Safety Testing and Applicable Standards
IPL and laser equipment can involve optical radiation, thermal energy, electrical hazards and software-controlled treatment functions. Manufacturers should identify applicable standards based on the product's design and intended use.
Potentially relevant standards include IEC 60601-1 for basic safety and essential performance of medical electrical equipment, IEC 60601-1-2 for electromagnetic compatibility, IEC 60601-2-22 for certain medical laser equipment, IEC 60601-2-57 for certain non-laser light source equipment and IEC 60825-1 for laser product safety.
Other standards may be relevant to usability engineering, software lifecycle processes and risk management. Examples include IEC 62366-1, IEC 62304 and ISO 14971. Their applicability depends on the product's design and regulatory route. Manufacturers should verify relevant editions and harmonisation status instead of assuming that every standard applies to every device.
Clinical Evaluation and Performance Evidence
Clinical evaluation supports the manufacturer's claims about device safety and performance. For medical devices, it must address conformity with the relevant General Safety and Performance Requirements. The evidence should be appropriate to the actual product, intended purpose, treatment applications and target users.
For applicable Annex XVI products, Article 61(9) of the MDR requires clinical evaluation to demonstrate performance rather than medical clinical benefit. Clinical investigations may be necessary unless reliance on existing clinical data from an analogous medical device is duly justified under the applicable provisions.
Manufacturers should carefully assess scientific publications and other evidence. Research involving a different wavelength, energy delivery system or treatment protocol may not automatically support the performance claims of a particular commercial device.
Quality Management and Notified Body Assessment
A quality management system helps manufacturers maintain consistent processes for design, purchasing, production, inspection, complaint handling and corrective actions. ISO 13485 is commonly used in the medical device industry to structure quality management activities. However, certification alone does not automatically establish complete MDR compliance.
Depending on classification and the applicable conformity assessment route, notified body involvement may be required. Manufacturers should select a notified body whose designation covers the relevant product scope and assessment activities. The assessment may include quality system review and examination of technical documentation.
Planning a Compliance Strategy
Regulatory planning should begin during product development rather than immediately before commercial launch. An early gap analysis can identify missing test reports, unsupported product claims, incomplete risk controls and weaknesses in technical documentation.
A practical compliance plan should connect classification, engineering verification, clinical evaluation, quality management and conformity assessment. Regulatory responsibilities should be assigned to relevant departments, and important decisions should be documented.
Conclusion
EU MDR compliance for IPL and laser devices requires a coordinated approach to regulatory classification, technical documentation, safety testing, clinical evaluation and quality management. Manufacturers must first establish whether their equipment is a medical device or an applicable Annex XVI product. They can then identify the requirements associated with the correct regulatory route and prepare the necessary evidence. A structured compliance strategy helps manufacturers identify gaps early, support product claims and maintain regulatory control throughout the product lifecycle.
systems and procedure packs systems and procedure packs